Saturday, July 5, 2008
Clinico-genomics publications
Sunday, June 1, 2008
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Publication related online materials
Model 1:In the general GBM population
Model 2:In patients treated by RT/TMZ (MGMT methylation status unavailable)
Model 3: In patients with partial or total resection and treated by RT/TMZ (MGMT methylation status available)
Kaplan Meier survival estimates for the main prognostic factors - Calibration of the nomograms
More on nomograms and survival models validation
- Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992; 11: 2093–109.
- Harrell FE Jr, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–87.
More on clinical prognostic factors for Glioblastoma
- Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704–10.
- Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40: 51–55.
- Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 1999; 86: 2117–23.
- Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003; 129: 477–84.
- Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 2003; 179: 8–15.
- Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004; 6: 227–35.
- Stelzer KJ, Sauvé KI, Spence AM, Gri. n TW, Berger MS. Corpus callosum involvment as a prognostic factor for patients with high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1997; 38: 27–30.
- Gamburg ES, Regine WF, Patchell RA, Strottmann JM, Mohiuddin M, Young AB. The prognostic signi. cance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2000; 48: 1359–62.
- Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N. Clinical prognostic factors in patients treated with malignant glioma treated with combined modality approach. Am J Clin Oncol 2004; 27: 195–204.
- Buckner JC. Factors influencing survival in high grade gliomas. Semin Oncol 2003; 30 (6 suppl 19): 10–14.
- Brown PD, Buckner JC, O’Fallon JR, et al. Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 2004; 59: 117–25.
- Brown PD, Balmann KV, Rummans TA, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 2006; 76: 283–91.
- Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and bene. t from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003.
- Hegi ME, Stupp R. Correlative studies in neuro-oncology trials: should they in. uence treatment? Curr Oncol Rep 2006; 8: 54–57.
- Mirimanoff. RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: a recursive partitioning analysis of EORTC 26981/22981-NCI.CE3 phase III
randomized trial. J Clin Oncol 2006; 24: 2563–69. - Hohwieler SM, Freidberg SH, Heatley GJ, Lo TC. Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas. Acta Oncol 1989; 28: 51–55.
- Stenning S, Freedman LS, Bleehen NM. Prognostic factors for high grade malignant glioma: development of a prognostic index. J Neurooncol 1990; 9: 47–55.
Other publications
Spectroscopy
Recommended reading :
Cost Effectiveness analyses
Recommended reading :
Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M ; Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium. Pharmacoeconomics. 2002;20(7):485-97. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M, Brochon D. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer. 2001 Sep;37(14):1768-74.
|
Clinico-Genomics ressources database
http://www.gorlia.net/genomics/Genomics_list.asp
Please suggest new entry by answering this post.
Treatment of other cancers
Head and Neck
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.
Breast
Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer. 2006 Dec;42(18):3178-85. Epub 2006 Oct 12.
Colorectal - Chronotherapy
Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F.A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. Chronobiol Int. 2008 Sep;25(5):680-96.
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F; European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006 Aug 1;24(22):3562-9.
Gastric
Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002 May;13(5):721-9.
Prognostic, Diagnostic, Treatment of Brain Tumors
Idbaih A, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen JL, Delattre O, Delattre JY, van den Bent M, Hoang-Xuan K.,Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.Neuropathology. 2008 Feb 26.
Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21. Comment in: Lancet Oncol. 2008 Jan;9(1):5-6 -more
Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51.
Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9.
Preusser M, Heinzl H, Gelpi E, Schonegger K, Haberler C, Birner P, Marosi C, Hegi M, Gorlia T, Hainfellner JA. Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Cancer. 2006 Jul 1;107(1):162-70.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.
Treatment of Brain Tumors
Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.J Clin Oncol. 2008 Oct 1;26(28):4659-65.
Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ; on behalf of the EORTC Brain Tumour Group investigators.Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008 Jan 11
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.
van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht ChJ, Allgeier A, Gorlia T; European Organization for Research and Treatment of Cancer Brain Tumor Group. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003 Jul 1;21(13):2525-8.
Career
Current Appointment (1999-...):
Thierry Gorlia is a member of the team allocated by the EORTC Data Center to provide scientific and logistic support to EORTC Brain Tumor and Translational Research Unit in the conduct of their cancer clinical trials. As a biostatistician of the EORTC, he provides statistical advice and expertise in the design, implementation, conduct, analysis and publications of the group’s clinical trials. He recently participated to the conduct and analysis of the EORTC 24971 of Taxotere in inoperable squamous cell carcinoma of the Head & Neck.
He reports to the Assistant Director for Biostatistics and work in close cooperation with the other members of his teams (coordinating physician, data manager,…), and with other units of the Data Center for particular projects.
His duties and responsibilities are:
• to advise the clinical group and the study coordinator on the optimal statistical design to be used in the conduct of their studies
• to help the study coordinator to write the study outline
• to coordinate the development of some of the protocols of his groups via the protocol help desk ,
• to handle the submission of all amendments for those protocols for which he coordinated the development.
• to be responsible for all statistical analyses of the data, whether for data monitoring committees, group meetings, congresses or for the publication of the results
• to present the results of these statistical analyses to the IDMC or to the groups
• to review all abstracts and publications written by investigators on the basis of Data Center reports and to write the statistical sections (material and methods, sometimes results) of the publications
• to maintain an up-to-date knowledge of the statistical techniques necessary for the proper design of trials and the analysis of the data (by reading publications in biostatistical journals, attending statistical meetings, etc)
• to identify and/or develop the software needed to carry out his work (meta-analysis, competing risks, …)
• to contribute to scientific research projects undertaken by the Data Center or the groups
• to carry out research on methodology related to the design, conduct or analysis of cancer clinical trials and to submit papers for publication
• to submit abstracts for presentation at statistical or medical meetings
• to give lectures during educational sessions or courses organized either by the EORTC or by other organizations.
Previous position at the EORTC Headquarter:
Biostatistican of the Health Economic Unit (June 1999-November 2003). Biostatistican of the Quality of Life Unit (June 1999-October 2001).
Consulting Statistician for SPSS Belgium in Leuven (September 1998 – May 1999)
Consulting Actuary for Unison Consultant Europe and Towers Perrin (April 1995-September 1998)
Research Actuary for The Free University of Brussels (ULB) (November 1992-November 1994)
Student actuary for AXA Insurance and Le Man Assurance (1990-1992)
Consulting Statistician for SONECOM (November 1995-November 2000)